Groundbreaking results from a major clinical trial, supported in part by the St. Baldrick’s Foundation, were unveiled today at the 66th Annual Meeting of the American Society of Hematology (ASH) in San Diego, Calif. The Children’s Oncology Group (COG) announced transformative findings that are set to redefine the standard of care for children with acute lymphoblastic leukemia (ALL).
This breakthrough—hailed as one of the most significant advancements in pediatric oncology in decades—represents a milestone made possible by 25 years of donations to St. Baldrick’s head-shaving events, fundraisers, and the generosity of dedicated donors.
The trial enrolled over 4,200 children and achieved unprecedented results:
A 96% three-year DFS rate for children receiving blinatumomab compared to 87.9% with chemotherapy alone.
Blinatumomab was shown to be well-tolerated, with minimal severe side effects, paving the way for reducing the use of older, more toxic chemotherapy drugs.
https://ash.confex.com/ash/2024/webprogram/Paper207450.html
